Non-toxic mucosal adjuvant

Details Non-toxic mucosal adjuvant Non-toxic mucosal adjuvant

2006-04-06

2009-02-03

Minnifield, N. M (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S265100, C424S234100, C424S245100, C424S264100, C424S236100, C424S204100, C424S254100, C424S206100, C424S217100, C424S261100, C424S282100, C424S231100, C424S250100, C424S249100, C424S240100, C514S002600, C514S012200

Reexamination Certificate

active

07485304

ABSTRACT:
A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating toxin, optionally comprising one or more amino acid additions, deletions or substitutions.

REFERENCES:
patent: 4328209 (1982-05-01), Finkelstein et al.
patent: 4428931 (1984-01-01), Tolman et al.
patent: 4666837 (1987-05-01), Harford et al.
patent: 4892827 (1990-01-01), Pastan et al.
patent: 4925792 (1990-05-01), Rappuoli
patent: 5032398 (1991-07-01), Kaslow
patent: 5085862 (1992-02-01), Klein et al.
patent: 5182109 (1993-01-01), Tamura et al.
patent: 5221618 (1993-06-01), Klein et al.
patent: 5244657 (1993-09-01), Klein et al.
patent: 5332583 (1994-07-01), Klein et al.
patent: 5358868 (1994-10-01), Klein et al.
patent: 5427788 (1995-06-01), Rappuoli et al.
patent: 5433945 (1995-07-01), Klein et al.
patent: 5668255 (1997-09-01), Murphy
patent: 5747028 (1998-05-01), Calderwood et al.
patent: 5770203 (1998-06-01), Burnette et al.
patent: 5773600 (1998-06-01), Burnette, III
patent: 5785971 (1998-07-01), Rappouli et al.
patent: 5786189 (1998-07-01), Locht et al.
patent: 5856122 (1999-01-01), Read et al.
patent: 5874088 (1999-02-01), Mekalanos
patent: 5874287 (1999-02-01), Burnette et al.
patent: 5882653 (1999-03-01), Kaper et al.
patent: 5889172 (1999-03-01), Pizza et al.
patent: 5908825 (1999-06-01), Fasano et al.
patent: 5925546 (1999-07-01), Pizza et al.
patent: 5942418 (1999-08-01), Loosmore et al.
patent: 5961970 (1999-10-01), Lowell et al.
patent: 5965385 (1999-10-01), Read et al.
patent: 5977304 (1999-11-01), Read et al.
patent: 5985284 (1999-11-01), Lowell
patent: 6019982 (2000-02-01), Clements
patent: 6030624 (2000-02-01), Russell et al.
patent: 6033673 (2000-03-01), Clements
patent: 6129923 (2000-10-01), Doidge et al.
patent: 6149919 (2000-11-01), Domenighini et al.
patent: 6350612 (2002-02-01), Rappouli et al.
patent: 6436407 (2002-08-01), Clements et al.
patent: 6440423 (2002-08-01), Clements et al.
patent: 6818222 (2004-11-01), Rappuoli et al.
patent: 6841155 (2005-01-01), Barchfeld et al.
patent: 6855321 (2005-02-01), Del Guidice et al.
patent: 7056521 (2006-06-01), Barchfeld et al.
patent: 7070781 (2006-07-01), Rappuoli
patent: 7115730 (2006-10-01), Pizza et al.
patent: 7279169 (2007-10-01), Rappuoli et al.
patent: 7291588 (2007-11-01), Pizza et al.
patent: 7384640 (2008-06-01), Holmes et al.
patent: 2001/0018056 (2001-08-01), Roberts
patent: 2002/0044939 (2002-04-01), Pizza et al.
patent: 2002/0187154 (2002-12-01), Rappouli
patent: 2003/0072764 (2003-04-01), O'Hagan
patent: 2003/0113338 (2003-06-01), Pizza et al.
patent: 2003/0170262 (2003-09-01), Pizza et al.
patent: 2003/0176653 (2003-09-01), Mason et al.
patent: 2004/0028690 (2004-02-01), Rappouli
patent: 2004/0109874 (2004-06-01), Chen et al.
patent: 2005/0106178 (2005-05-01), O'Hagan
patent: 2005/0106180 (2005-05-01), Barchfeld et al.
patent: 2006/0057155 (2006-03-01), Masignani et al.
patent: 2006/0159701 (2006-07-01), Barchfeld et al.
patent: 2006/0177469 (2006-08-01), Rappuoli
patent: 2007/0110809 (2007-05-01), Magagnoli et al.
patent: 0396964 (1990-11-01), None
patent: 0462534 (1991-12-01), None
patent: 0688868 (1995-12-01), None
patent: WO 92/19265 (1992-11-01), None
patent: WO 93/13202 (1993-07-01), None
patent: WO 95/09649 (1995-04-01), None
patent: WO 95/17211 (1995-06-01), None
patent: WO 95/34323 (1995-12-01), None
patent: WO 96/06627 (1996-03-01), None
patent: WO 99/58145 (1999-11-01), None
patent: WO 00/18434 (2000-04-01), None
patent: WO 2006128296 (2006-12-01), None
Wu et al, Vaccine, 1998, 16/2-3:286-292.
Lycke, Immunology Letters, 2005, 97:193-198.
Lomada et al, Vaccine, 2004, 23:555-565.
Tritto et al, J. Immunology, 2007, 179:5346-5357.
Takahashi et al, Vaccine, 2006, 24:3591-3598.
Petrovska et al, Vaccine, 2003, 21:1445-1454.
Kende et al, Vaccine, 2007, 3219-3227.
Sanchez et al, JBC, Sep. 6, 2002, 277/36:33369-33377.
Tebbey et al, Vaccine, 2000, 18:2723-2734.
O'Hagan et al, Vaccine, 1999, 17:2229-2236.
Hagiwara et al, Vaccine, 1999, 17:2918-2926.
Yuki et al, Rev, Med. Virol. 2003, 13:293-310.
Ugozzoli et al, J. Infectious Diseases, 2001, 183:351-354.
Holmgren et al, Expert Rev. Vaccines, 2003, 2/2:205-217.
Douce et al, Vaccine, 1998, 16/11-12:1065-1073.
Freytag et al, Curr. Top. Microbiol Immunol., 1999, 236:215-36.
DeMagistris et al, Dev. Biol. Stand. 1998, 92:123-126.
O'Hagan, J. Pharm. Pharmacol. 1998, 50/1:1-10 (abstract only).
Anderson, et al., “Immunogens Consisting of Oligosaccharides from the Capsule of Haemophilus Influenzae Type b Coupled to Diphtheria Toxoid or the Toxin Protein CRM197,”J. Clin. Invest.76:52-59 (1985).
Anderson, “Antibody Responses To Haemophiles Influenzae Type B And Diptheria Toxin Induced By Conjugates Of Oligosaccharides Of The Type B Capsule With The Nontoxic Protein CRM 197,”Inf.&Immun.39(1):233-238 (1983).
Baqar, et al., “Safety And Immunogenicity Of A Prototype Oral Whole-Cell Killed Campylobacter Vaccine Administered With A Mucosal Adjuvant In Non-Human Primates,”Vaccine,13(1):22-28 (1995).
Bartley, et al., “Pertusis Holotoxoid Formed in vitro with a Genetically Deactivated S1 Subunit,”PNAS USA86:8353-8357 (1989).
Baudner, et al., “The Concomitant Use Of The LTK63 Mucosal Adjuvant And Of Chitosan-Based Delivery System Enhances The Immunogenicity And Efficacy Of Intranasally Administered Vaccines,”Vaccine21:3837-3844 (2003).
Bennett, et al., “A Comparison of Commerically Available Adjuvants for Use in Research,”J. Immunol. Methods153:31-40 (1992).
Black, et al., “Construction and Characterizations ofBordetella pertussisToxin Mutants,”Infection&Immunity55(10):2465-2470 (1987).
Boslego, et al., “Gonorrhea Vaccines,” Vaccines and Immunotherapy Chapter 17, pp. 211-223 (1991).
Bowie, et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science247:1306-1310 (1990).
Brandtzaeg, “Overview of the Mucosal Immune System,”Current Topics Microbiol.&Immunol.146:13-25 (1989).
Burnette, “The Advent of Recombinant Pertussis Vaccines.”Biotechnol.8:1002-1005 (1990).
Burnette,Vaccine Research&DevelopmentsMarcel Dekker Inc., New York, New York (1992).
Burnette, “AB5 ADP-Ribosylating Toxins: Comparative Anatomy and Physiology,”Structure2(3):151-158 (1994).
Burnette, et al., “Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for Arginine 7 causes loss of activity,” Infect. & Immun. 59:4266-4270 (1991).
Carbonetti, et al., “Intracellular Delivery of Cytolytic T-Lymphocyte Epitope Peptide by Pertussis Toxin to Major Histocompatibility Complex Class I Without Involvement of the Cytosolic Class I Antigen Processing Pathway,”Infection&Immunity67(2):602-607 (1999).
Chen, “Recent advances in mucosal vaccine development,”J. Controlled Release67:117-128 (2000).
Cheng, et al., “The Role Of Camp In Mucosal Adjuvanticity OfEscherichia coliHeat-Labile Enterotoxin (LT),”Vaccine18:38-49 (2000).
Clements, et al., “Adjuvant activity ofEscherichia coliheat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens,”Vaccine6:269-277 (1988).
Communication to EPO Concerning Replacement Claims for Filing with the EPO in Application No. 99922284.7 (2003).
Czerkinsky, et al., “Oral Administration of a Streptococcal Antigen Coupled to Cholera Toxin B Subunit Evokes strong Antibody Responses in Salivary Galnds and Extramucosal Tissues,”Infect.&Immun.57:1072-1077 (1989).
de Haan, et al., “Mucosal Immunogenicity of theEscherichia coliHeat-Labile Enterotoxin: Role of the A Subunit,”Vaccine14(4):260-266 (1996).
de Haan, et al., “Mutational Analysis of the Role of ADP-Ribosylation Activity in the Adjuvant Properties of theEsc

Affiliated with

Also associated with

Rating

Non-toxic mucosal adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Non-toxic mucosal adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-toxic mucosal adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4101723